Drug Database
MF

MF-59 (MF59)

✓ Approved

Novartis AG · Small Molecule · Small Molecule

What is MF-59?

MF-59 is a small molecule developed by Novartis AG. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesMF59
CompanyNovartis AG
Drug ClassSmall Molecule
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Therapeutic Indications

MF-59 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedThe Journal of dermatology2026-06-09

Hypopigmented Mycosis Fungoides With Childhood-Onset and Middle-Aged Onset: Two Case Reports Focusing on the Cutaneous Immune Microenvironment.

Yahagi Yoko Y, Fujimura Taku T, Yoshida Arisa A, Asano Yoshihide Y

Hypopigmented mycosis fungoides (MF) is a rare clinical variant of MF that often presents in childhood or young adulthood and is typically associated with an indolent course. In contrast to classic MF, hypopigmented MF frequently shows a CD8+ T-cell-predominant phenotype, and cytotoxic immune responses have been implicated in melanocyte injury; however, the cutaneous immune microenvironment across different ages of onset remains incompletely characterized. We reported two cases of hypopigmented MF with distinct ages of disease onset and evaluated lesional immune profiles by immunohistochemistry, focusing on CD8, FOXP3, CXCL10, and CCL19. In both cases, the epidermotropic infiltrate was CD8-positive T-cell dominant, accompanied by scarce FOXP3-positive cells and increased expression of CXCL10 together with CCL19. These shared features support the concept that a Tc1-associated cytotoxic immune milieu, accompanied by scarce FOXP3-positive cells, may be associated with hypopigmentation in hypopigmented MF, irrespective of the age at clinical presentation.

PMID 42261000
Read full article →
PubMedAnnals of clinical and laboratory science2026-06-09

Systemic Immune-Inflammation Index as a Prognostic Marker in Mycosis Fungoides.

Kurmuş Gökçe Işıl GI, Menteşoğlu Dilek D, Kartal Selda Pelin SP

The systemic immune-inflammation index (SII) is considered a prognostic factor in numerous malignancies and is associated with disease progression. Although systemic inflammation has been investigated in mycosis fungoides (MF), the prognostic significance of SII remains unclear. This study aimed to evaluate the association between SII and disease stage in MF and to determine whether elevated SII values are related to advanced-stage disease. A retrospective analysis was performed on 126 patients diagnosed with MF at a tertiary center. The prognostic utility of SII was assessed alongside neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and clinicopathological variables including age, sex, disease stage, lactate dehydrogenase, and beta-2 microglobulin levels. Receiver operating characteristic curve analysis demonstrated that SII had the highest area under the curve (AUC) among the evaluated markers. For distinguishing MF patients from controls, SII yielded an AUC of 0.828 at a cut-off value >410.61 (sensitivity 70.63%, specificity 84.40%). In differentiating early and advanced MF stages, SII showed the highest diagnostic accuracy (AUC 0.891, p<0.001; sensitivity 80.95%, specificity 88.57%) with an optimal cut-off value of 891.02. SII is a cost-effective and accessible prognostic marker for advanced-stage MF and may aid in identifying high-risk patients who benefit from closer monitoring or earlier intervention.

PMID 42259538
Read full article →
PubMedPhysics in medicine and biology2026-06-09

Anatomy-based parameter selection and efficiency-quality balance in radixact helical tomotherapy.

Gui Longgang L, Poo Yin Y

To investigate the effects of jaw width, pitch, and modulation factor (MF) on dose distribution quality and delivery efficiency in Radixact helical tomotherapy for targets with different anatomical characteristics. Approach: Eighty patients were divided into four groups (n=20 each) based on target volume, shape complexity, and organ-at-risk (OAR) geometry: Group A (small volume/high gradient), Group B (medium volume/complex wrapping), Group C (medium volume/simple), and Group D (large volume/long-axis). Jaw width (1.0/2.5/5.0 cm), pitch (0.172-0.430), and MF (1.2-4.2) were optimized using a stepwise control variable approach. A composite efficiency-quality score (EQS) was developed for comprehensive evaluation of treatment plans. Dynamic jaw mode showed good longitudinal penumbra control, with both 2.5 cm and 5.0 cm settings achieving results comparable to 1.0 cm static mode (P > 0.05). Its impact was most pronounced for Group D, where 5.0 cm mode showed a 43.6% reduction in beam-on time compared to 2.5 cm mode, while maintaining similar plan quality. Pitch values had different impact across the groups. For group B, optimal pitch settings were critical to effectively navigate shape complexity and ensure adequate dose modulation. Furthermore, excessive MF (4.0) reduced the gamma pass rate to 89.2% for Group A, falling below the 90% clinical threshold. Radixact physical parameters should be individualized based on specific target anatomy. The proposed EQS method and associated recommendations provide an anatomy-based approach to treatment planning optimization, attempting to balance delivery efficiency and plan quality.

PMID 42259373
Read full article →
PubMedJournal of nutrition education and behavior2026-06-09

Differences in Food Consumption Among Children After the Implementation of Warning Labels in Uruguay.

Brunet Gerónimo G, Curutchet María Rosa MR, Ares Gastón G

To evaluate changes in food consumption among children aged 6 to 59 months following the implementation of warning labels on foods high in sugars, sodium, fats, and saturated fats in Uruguay. A before-and-after design was used to assess changes in food consumption between 2 cross-sectional samples of children aged 6-59 months surveyed before (2018) and after (2023) the implementation of the policy. Generalized linear models (binomial distribution and logit link function) were conducted for 2 age groups (6-23 and 24-59 months), adjusting for potential confounders and including interactions between cohort and household income. Between 2018 and 2023, children aged 6-23 months presented significant reductions in the consumption of several product categories targeted by the policy. Both age groups had lower odds of consuming sodas, artificial juices, and flavored waters. The findings showed significant reductions in the likelihood that children consumed several categories of products typically high in nutrients linked to risk of noncommunicable diseases, consistent with a potential influence of warning labels.

PMID 42262300
Read full article →
PubMedBioresource technology2026-06-09

Magnetic bio preconcentration (MBP) for chemical-free cost-effective and low carbon sewage organics recovery.

Ling LanXin L, Zhong JingRong J, Wang Zhaoying Z, Xing YuKun Y et al.

A magnetic bio-preconcentration (MBP) process combining magnetic seeds (MS) and magnetic field (MF) was proposed to address sewage organic matter (OM) capture-separation trade-off issues for resource recovery, optimally recovering 82.4% of chemical oxygen demand (COD) in raw sewage with mineralization of 12.3%. Separability improved markedly with 10-min settled Sludge Volume (SV10) decreasing to 46% and the effective concentration factor (η) increasing to 10.5, due to MBP-driven restructuring of extracellular polymeric substances (EPS). Soluble EPS (S-EPS) and tightly bound EPS (TB-EPS) increased to 69.00 and 186.17 mg/L, respectively, while loosely bound EPS (LB-EPS) remained below 20% of total EPS. In MBP, protein (PN) was enriched in S-EPS (25.89 mg/L) and humic acids (HA) migrated from LB-EPS (13.05 mg/L) to S-EPS (32.25 mg/L), consistent with strengthened PN-/HA detected in 3D excitation-emission matrix fluorescence spectroscopy. Time-of-flight secondary ion mass spectrometry demonstrated enrichment of hydrophilic PN and polysaccharide (PS) in S-EPS, increasing hydrogen-bonding interaction sites for OM capturing. Quinone-like HA were recognized major promotor via redox mediation, while aniline-/phenol-like structures were identified to promote MS-EPS coupling and retention of aromatic/hydrophobic OM by aromatic interactions. Principally, MBP supported LB-EPS as an exchange layer and TB-EPS enriched in structural PN and PS, reinforcing stable cellular flocculation and microenvironment. With an energy consumption of 0.023 kWh/m3 and a carbon emission of 0.022 kg CO2eq/m3 at operational cost of ∼0.004 USD/m3, MBP offered a low-carbon alternative for sewage preconcentration towards sustainability.

PMID 42259451
Read full article →
PubMedCritical care medicine2026-06-09

Hospital-Level Variation in Early Tracheostomy and Withdrawal of Life-Sustaining Treatment in Severe Traumatic Brain Injury: A Nationwide Analysis.

Katsura Morihiro M, Ikenoue Tatsuyoshi T, Ambrose Corey C, Braschi Caitlyn C et al.

Early tracheostomy (ET) in severe traumatic brain injury (TBI) is often considered during periods of prognostic uncertainty and evolving goals of care. We aimed to evaluate the association between hospital-level tendency for ET and the frequency of withdrawal of life-sustaining treatment (WLST) following tracheostomy in patients with severe TBI. Retrospective cohort study. Trauma centers participating in the American College of Surgeons Trauma Quality Improvement Program (2016-2021). Adult patients 20-89 years old with severe TBI (head Abbreviated Injury Scale: 3-5 and Glasgow Coma Scale: 3-8), who received mechanical ventilation and underwent tracheostomy. None. A mixed-effects logistic regression model was developed to estimate each hospital's unique risk-adjusted odds ratio (AOR) for ET (≤ 7 d after injury), and hospitals were stratified into low-, medium-, and high-tendency groups based on the AOR for ET. The association between hospital-level tendency for ET and WLST post-tracheostomy was assessed. Among 22,156 patients with severe TBI treated at 417 hospitals, the ET rates were 16.8%, 30.1%, and 47.7% in the low-, medium-, and high-tendency hospitals, respectively. WLST following tracheostomy occurred in 2.6%, 4.8%, and 9.6% of patients 20-39, 40-59, and 60-89 years old, respectively. After multilevel case-mix adjustments, a high hospital-level tendency for ET was associated with increased odds of WLST post-tracheostomy (AOR, 1.35; 95% CI, 1.10-1.66; p = 0.004), with the highest point estimate observed among patients 40-59 years old (AOR, 1.39; 95% CI, 1.01-1.91). Hospitals with a higher tendency to perform ET had a greater likelihood of WLST following tracheostomy. These findings highlight practice variability in tracheostomy timing that may occur in the setting of prognostic uncertainty early after severe TBI and may influence downstream care pathways.

PMID 42262510
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about MF-59